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Traumatic brain injury (TBI) affects an estimated 1.7 million people in the United States
and is a contributing factor to one third of all injury related deaths annually. According
to the CDC, approximately 75% of all reported TBIs are concussions or considered
mild in form, although the number of unreported mild TBIs (mTBI) and patients not
seeking medical attention is unknown. Currently, classification of mTBI or concussion
is a clinical assessment since diagnostic imaging is typically inconclusive due to subtle,
obscure, or absent changes in anatomical or physiological parameters measured using
standard magnetic resonance (MR) or computed tomography (CT) imaging protocols.
Molecular imaging techniques that examine functional processes within the brain, such
as measurement of glucose uptake and metabolism using [18F]fluorodeoxyglucose and
positron emission tomography (FDG-PET), have the ability to detect changes after mTBI.
Recent technological improvements in the resolution of PET systems, the integration
of PET with magnetic resonance imaging (MRI), and the availability of normal healthy
human databases and commercial image analysis software contribute to the growing
use of molecular imaging in basic science research and advances in clinical imaging. This
review will discuss the technological considerations and limitations of FDG-PET, including
differentiation between glucose uptake and glucose metabolism and the significance of
these measurements. In addition, the current state of FDG-PET imaging in assessing mTBI
in clinical and preclinical research will be considered. Finally, this review will provide insight
into potential critical data elements and recommended standardization to improve the
application of FDG-PET to mTBI research and clinical practice.
Keywords: fluorodeoxyglucose, FDG, positron emission tomography, mTBI, clinical research, experimental
research, traumatic brain injury
INTRODUCTION
Traumatic brain injury (TBI) is a growing public health concern
worldwide and the Centers for Disease Control and Prevention
(CDC) indicate about 1.7 million new cases are reported in the
United States (US) each year. Further, there are over 1.35 million
emergency room visits and 275,000 hospitalizations for nonfatal
TBI each year in the US, and approximately 40% of these individ-
uals suffer from long-term disability due to their injury (Selassie
et al., 2008; Corrigan et al., 2010; Faul et al., 2011). The CDC
statistics do not account for military head injury but, according to
the Defense and Veterans Brain Injury Center (DVBIC), approx-
imately 280,000 service members have been diagnosed with a
TBI between 2000–2013. The number of new diagnoses, which
are typically mild TBI (mTBI), has almost tripled since 2000
(10,000–30,000), indicating an increased awareness and improved
assessment by the armed forces. While the majority of TBIs occur
in males aged 15–24, attention must also be paid to females,
pediatric, and geriatric populations, which are all represented in
TBI patient populations and present unique challenges (Thurman
et al., 2007; Wilde et al., 2012).
The International Classification of Diseases, 9th revision,
(ICD-9), defines TBI as a skull fracture, concussion, intracra-
nial injury of other and unspecified nature, or unspecified head
injury (Bazarian et al., 2006). The Brain Injury Association of
America (BIAA) recently adopted the following definition of TBI:
“TBI is defined as an alteration in brain function, or other evi-
dence of brain pathology, caused by an external force.” Injury
severity is currently based on several diagnostic criteria includ-
ing loss of consciousness (LOC), amnesia and altered mental
state (Ruff et al., 2009). mTBI is characterized by the presence
of at least one of those criteria, and further restricted to LOC
not to exceed 30min, post-injury antero-or-retrograde amnesia
not exceeding 24 h, or altered mental state (confusion, dizzi-
ness, etc.) not exceeding 24 h (Ruff et al., 2009). Patients with an
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mTBI generally have a Glasgow Coma Scale (GCS) score between
13–15 (Jagoda, 2010). However, these diagnostic criteria are based
on clinical observations and patient self-reporting and may not
provide adequate sensitivity and specificity for mTBI.
Due to the challenge in clinically assessing mTBI, there is
a growing demand for clinical neuroimaging assessment tech-
niques. Traditionally, physicians have relied on computed tomog-
raphy (CT) and magnetic resonance imaging (MRI) to identify
intracranial bleeding, lesions and skull fractures. However, mTBIs
most often present without any observable defect on CT or stan-
dard MRI and, furthermore, a significant fraction of patients
are unsuitable for MRI due to other health concerns, which is
especially apparent in service members with metal fragments.
The chronic deficits that many mTBI patients experience after
injury such as headache, dizziness, fatigue, depressed, or anxious
mood, sleep disturbance, light sensitivity, forgetfulness, and con-
centration difficulties are potentially life altering and cannot be
predicted with the sensitivity currently available with CT or MRI
(Taylor et al., 2010).
Positron emission tomography (PET) imaging provides
exquisite sensitivity for small molecular changes, on the order
of nanogram compared to milligram or microgram for MRI or
CT, and can provide important information regarding changes
in brain metabolism after TBI. For example, depressed glucose
metabolism has been observed after TBI and the magnitude and
duration of this depression has been correlated with worse behav-
ioral and cognitive outcomes (Giza and Hovda, 2001). These
initial findings into cerebral glucose utilization were obtained
using deoxyglucose (DG) labeled with 14C and autoradiogra-
phy (Sokoloff et al., 1977). DG was selected over glucose since
glucose is fully metabolized in the brain while DG is phospho-
rylated but then not further metabolized, becoming trapped in
the cell with a slow clearance rate. For non-invasive imaging, a
positron-emitting isotope such as 18F can be attached to DG,
resulting in [18F]fluorodeoxyglucose (FDG) that accumulates in
brain tissue in proportion to glucose uptake and phosphory-
lation and is quantifiable using PET imaging (Reivich et al.,
1979). This review will summarize the use of FDG-PET to non-
invasively measure alterations in cerebral glucose metabolism
after TBI.
PET TECHNOLOGY
PET has two key components: (1) a radioactive isotope tagged
to a physiologically relevant molecule and introduced into the
body; and (2) a set of radiation detectors located outside of the
body that can quantify the location and amount of the tagged
molecules. The radioactive isotope is characterized by positron
emission, which entails the detection of the two 511 keV pho-
tons that are simultaneously emitted during pair annihilation
(positron-electron interaction) and travel in opposite directions,
antiparallel or 180◦. The PET detector is a type of tomograph, a
detector that can produce a 3-dimensional (3D) representation of
an object. The positron source is internal to the patient/subject
and the two emitted photons, after traversing the body, interact
in two detectors embedded in a full detector ring that surrounds
the subject. Sophisticated algorithms are used to reconstruct a
2D or 3D representation of the radioisotope spatial distribution
by combining information from a large number of individual
photon detectors (Kapoor et al., 2004).
New developments in PET technology have improved image
contrast and spatial resolution while maintaining high sensitivity,
yet PET still suffers from limited spatial resolution. Spatial reso-
lution for clinical PET acquisitions routinely approach approxi-
mately 5–10mm whereas the spatial resolution of small animal
PET is typically 1–2mm. Spatial resolution and sensitivity are
important factors to consider in preplanning PET studies. Good
spatial resolution is essential when it is important to distinguish
between small or adjacent structures; for example, it may not be
realistic to differentiate between each of the sub-structures of the
human amygdala or sub-regions in a mouse brain. Sensitivity is
also important both in terms of the overall amount of radioiso-
tope that can be delivered to the brain, as well as in terms of
targeting injured or altered tissue relative to normal tissue, termed
target-to-background ratio.
Several factors affect accurate PET quantification: data cor-
rections, static or dynamic acquisition, blood glucose level (GL),
patient movement, partial volume effects, and image reconstruc-
tion and quantification strategy. It should be noted that “quantifi-
cation” is used in the general form and can be further subdivided
into absolute activity, absolute physiology, or relative or semi-
quantitative techniques. These topics will be discussed briefly as
they pertain to cerebral FDG quantification.
PET QUANTITATION
PET imaging is inherently quantitative due to the counting of
individual photons and the direct relationship between counts
and activity concentration. The advantage of quantification is
the ability to directly compare results across different brain
regions, across time, across subjects, and across studies. The
term “quantitative” implies that the results can be reduced to
usable SI units. However, accurate and precise activity quantifi-
cation is challenging, with physiologic quantification even more
difficult. Clinicians typically prefer reasonable semi-quantitative
techniques that include relatively short scan times, are easy to
implement, and require little or no blood sampling. Yet, research
protocols may desire accuracy and precision of quantification
over practical factors and may require longer scan times, serial
blood sampling, high resolution scan protocols, and robust image
acquisition and processing techniques.
In the specific case of monitoring glucose metabolism, since
FDG is phosphorylated by hexokinase but is not further metab-
olized, the measured FDG activity concentration is not a direct
measurement of the metabolic rate for glucose consumption
(MRGlc) and additional factors must be determined. This sec-
tion will discuss the various approaches to image acquisition,
quantification, and analysis.
Metabolic rate for glucose
The process of determining the MRGlc in vivo is complex
and requires the use of advanced models of tracer kinetics
and measurements or estimates of several parameters - some
of these measurements are invasive. Several good review arti-
cles have been published on this topic and, therefore, this sec-
tion will only focus on the most significant factors to consider
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for MRGlc quantification (Sokoloff et al., 1977; Phelps et al.,
1979; Reivich et al., 1979; Huang, 2000; Yamaji et al., 2000; Yu
et al., 2009). A well-known quantification model for FDG is the
two-tissue compartment model (or three-compartment model;
Figure 1).
It should be noted that Figure 1 represents a single PET voxel
where all three concentrations are measured simultaneously in
each voxel and all three concentrations change over time (C =
CP + CTFDG + CTFDG-6-PO4) where CP and CT are FDG con-
centrations in plasma or tissue, respectively. Since DG competes
with glucose for hexokinase, the non-radioactive GL or glycemia
in plasma should be measured throughout the study. This is
especially important for small animal imaging since anesthesia
induces hyperglycemia, which increases FDG concentration in
plasma and reduces tissue uptake (Toyama et al., 2004a; Lee et al.,
2005). Furthermore, since the transport across the blood-brain-
barrier and the rate of phosphorylation of FDG and glucose differ,
FDG uptake (MRFDG) must be converted to the MRGlc by a cor-
rection factor known as the lumped constant (LC) (Sokoloff et al.,
1977; Phelps et al., 1979; Reivich et al., 1985; Spence et al., 1998).
LC = MRFDG
MRGlc
This LC is generally not measured for each patient but can be esti-
mated based on previous studies that obtained robust measures of
radioactivity and glucose blood concentrations. In these previous
studies, the LC did not show significant variation under normal
physiological conditions (Gjedde and Diemer, 1983; Kuwabara
et al., 1990). However, TBI can result in abnormal physiologic
conditions and the LC may vary significantly after TBI. Marklund
et al. provides evidence that the LC in rats changes regionally
immediately after TBI (Marklund et al., 2009). Likewise, Wu et al.
also show a significant decrease in global LC from 0.65 ± 015
to 0.43 ± 0.19 in humans following TBI (Wu et al., 2004a).
The LC is an essential parameter in determining the MRGlc, as
shown in the equation below, and an underappreciated decrease
FIGURE 1 | A two-compartment model that symbolizes FDG transport
from blood plasma to tissue, as freely available FDG, with subsequent
trapping in the cell by phosphorylation to FDG-6-PO4. The
compartment concentrations of FDG are represented by plasma (Cplasma),
interstitial space (Cfree), and cellular (Ccell). K1 is the perfusion constant (ml
of blood/g of tissue/min), and k2, k3, and k4 are rate constants (min−1) for
diffusion back to blood plasma, phosphorylation of FDG, and
de-phosphorylation, respectively. The arrow size represents the relative
magnitude of the rate constants. The dashed vertical line indicates the
blood-brain-barrier and the dashed arrow indicates the de-phosphorylation
of FDG, which is typically insignificant (k4 is 0 for the “irreversible” model).






where rate constants K1–k3 are estimated from previous studies
as a priori knowledge or determined from the kinetic model and
PET data acquired dynamically over several frames. In general,
two components must be known to perform kinetic analysis: (1)
the opportunity for the tissue to accumulate the tracer, which
is obtained from the time-dependent blood FDG concentration
function and (2) the actual tissue uptake, which is obtained from
the region-specific tissue time-activity curve (TAC). The blood
FDG concentration, or arterial input function (AIF), is obtained
by either frequent sampling of the arterial blood or by monitor-
ing an image-derived blood pool such as the left ventricle of the
heart (de Geus-Oei et al., 2006; Tantawy and Peterson, 2010).
The TACs are generated from identifying a region of interest
(ROI) on each frame of a dynamic study and dividing the mean
value (MBq/pixel) by the frame length in units of time (s). The
Patlak plot is a graphical analysis technique that was developed
for irreversible tracers such as FDG and estimates the MRGlc
by calculating the slope of the transformed uptake curve (Patlak
et al., 1983; Patlak and Blasberg, 1985). The Patlak plot estimates a
combination of constants [K1k3/k2 + k3] based on a steady-state
condition at later time points, when plasma FDG concentration is
considered constant and when the free and plasma compartments
are in equilibrium (Patlak et al., 1983; Patlak and Blasberg, 1985).
The Patlak analysis assumes that FDG is irreversibly trapped
(k4 = 0) and requires a fully sampled AIF and a dynamic acquisi-
tion at steady state, when FDG shows linear behavior (15–20min
after injection). When comparing various kinetic models and
graphical techniques, the Patlak method showed the most sta-
ble coefficient of variation but underestimated the MRGlc (Feng
et al., 1995).
A lack of precision or reproducibility in MRGlc is observed
in human and small animal populations due to the variability
associated with PET imaging and the uncertainty in the estimated
parameters, kinetic models, or a priori knowledge. For example,
the LC for rats has been reported to be 0.46–0.71 while humans
demonstrate a LC of 0.42–0.81 depending on the measurement
technique and assumptions regarding dephosphorylation (Huang
et al., 1980; Ackermann and Lear, 1989; Hasselbalch et al., 1998,
2001; Wu et al., 2003; Krohn et al., 2007). Most recently, Alf et al.
summarized small rodent FDG studies and found an almost five-
fold range for cerebral MRGlc values in mice (Alf et al., 2013).
For clinical purposes, the “Society of Nuclear Medicine Procedure
Guideline for FDG PET Brain Imaging” notes that absolute quan-
tification techniques are generally not necessary due to the high
inter-individual fluctuation of the MRGlc (Waxman et al., 2009).
Standardized uptake value
The most widely used preclinical and clinical image analysis
parameter for FDG-PET imaging is the standardized uptake
value (SUV). Strictly speaking, this is not an absolute quan-
titative approach, but rather can be described as a standard
approach to scaling between subjects. This simple parameter is
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not without controversy and scales the measured FDG uptake by




where Ct is the decay-corrected activity concentration in the
tissue, ID is the injected dose (pre-injection syringe activity—
post-injection syringe residual activity), and wt is the patient
weight, lean body mass, or body surface area (Zasadny and Wahl,
1993; Sugawara et al., 1999). Activity concentration is typically
provided in MBq/cc, which can be converted to MBq/kg by divid-
ing by tissue density (1 g/cc). Regional changes can be analyzed by
determining the maximum SUV, based on a single pixel value, or
a peak SUV value that is based on the average SUV within a small,
fixed-sized region (Vanderhoek et al., 2012). The SUV strongly
depends on FDG clearance and uptake kinetics, which can vary
between subjects, and the SUVmay not serve as a sufficient proxy
for glucose metabolism (Yamaji et al., 2000). For instance, the
liver is responsible for clearing FDG from the blood at early time
points, and numerous liver conditions can produce a large range
of FDG clearance rates (Cheng et al., 2013). It is assumed that
the time integral of the plasma FDG TAC is proportional to the
injected dose and inversely proportional to patient weight or body
surface area (Huang, 2000). The former assumption implies that
this relationship is not affected by other factors, which may not
be accurate due to alterations in FDG clearance and differences
in blood GLs that [ID/wt] do not reflect. Ishizu et al. showed
an approximate 20% coefficient of variation for the ratio of the
time integral of the FDG TAC to ID/wt in the cerebral cortex of
10 patients under two different conditions, normal control and
hyperglycemia (Ishizu et al., 1994). Other sources of error in the
calculation of the SUV include biologic factors such as blood
GL, uptake period, patient motion, and sedation, and techno-
logical factors such as scan acquisition and image reconstruction
parameters, ROI definition, scanner normalization, and calibra-
tion, and FDG administration (Keyes, 1995; Boellaard et al., 2004;
Boellaard, 2009; Adams et al., 2010). Errors in the administration
of FDG can be especially significant for small animal PET imag-
ing where the risk of extravascular/perivascular administration is
high. Brain FDG uptake is also a function of time post-injection
and generally increases to a plateau and then slowly decreases
due to elevated levels of glucose-6-phosphatase, which hydrolyzes
glucose-6-phosphate to free glucose and allows FDG to exit the
compartment. Scans conducted at different times post-injection
may result in significantly different average tissue activity con-
centrations and SUVs. This is a critical element when planning
longitudinal FDG neuroimaging studies in humans or animals.
Overall, many small factors affect SUV results and the use of
inconsistent techniques for FDG brain imaging can contribute to
variations in SUVs exceeding 50% (Ishizu et al., 1994; Westerterp
et al., 2007; Takahashi et al., 2008; Boellaard, 2009).
Relative uptake value
The relative uptake value (RUV), also termed the reference tis-
sue or normalized uptake value, represents the FDG uptake in a
specific ROI normalized by the uptake in a stable region, which
is unaffected by the process under investigation. The RUV is,
strictly speaking, a semi-quantitative ratio or index and should
not be confused with MRGlc, since no metabolic information
is obtained. However, the ratio is a simplified parameter that is
highly reproducible, minimizes or eliminates many of the fac-
tors contributing to variations in quantification, and may serve
as a biomarker for TBI. Several TBI studies using FDG in humans
and small animals have normalized the specific ROI by the global
brain uptake, contralateral region, or cerebellum (Nakayama
et al., 2006; Kato et al., 2007; Nakashima et al., 2007; Liu et al.,
2010; Zhang et al., 2010; Selwyn et al., 2013). Liu et al. have
shown that the cerebellum is a stable reference region follow-
ing a severe lateral fluid percussion (LFP) injury in a rat (Liu
et al., 2010), while other studies have normalized PET images
to the global brain activity (Yakushev et al., 2008; Dukart et al.,
2010). One drawback to the RUV is the lack of physiological cor-
relation and the possibility of nullifying regional changes with
changes in the reference region, if the reference region is unstable.
However, the RUV can be quite robust and relatively insensitive
to differences in techniques, which is preferable for longitudinal
studies or attempting to measure small changes in FDG uptake
after mild forms of TBI—when precision is paramount. Yet, it is
imperative to validate the choice of reference region in the specific
injury model or, at minimum, acknowledge the limitations of the
quantification.
Image processing and analysis
Image reconstruction, processing, and analysis parameters can
have a profound effect on FDG brain quantification (Adams et al.,
2010). Image analysis methods can generically be divided into two
broad categories: ROI and voxel-based analysis (VBA). ROI anal-
ysis involves extracting summary data from one or more regions.
Regions can be defined using either anatomical or radiotracer-
derived boundaries and either hand drawn or generated by auto-
mated segmentation routines such as FreeSurfer software (Reuter
et al., 2012). The ROI summary is the average mean concentra-
tion within the region, but the minimum, median, or maximum
values can also be considered. ROI results have shown high vari-
ability depending on inter- and intra-reader differences in ROI
placement and geometry drawn (Habte et al., 2013). These vari-
ations, which are due to the relatively poor spatial resolution of
PET imaging and the difficulty in identifying anatomical regions,
can be minimized by co-registering PET images to same-subject,
high-resolution anatomical MR images, or spatially normalizing
to a standard brain atlas. Anatomic standardization methods are
widely used today and allow PET images to be transformed into
a standard space using spatial normalization techniques (Friston
et al., 1990; Roland and Zilles, 1994; Ashburner, 2012).
Voxel-based methods, first widely developed by Friston et al,
popularized through the Statistical Parametric Mapping (SPM)
software package, considers each voxel to be a single ROI (Friston
et al., 1994). The smaller ROI is penalized with a poorer sig-
nal to noise ratio (SNR) and a related loss of statistical power
due to the necessity for Bonferroni-style correction for multiple
comparisons (Bennett et al., 2009). Even though VBA has been
used extensively and is widely regarded as the gold standard in
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functional neuroimaging analysis, VBA is heavily dependent on
accurate coregistration and spatial normalization of brain images
across subjects and time. However, a weakness shared by VBA,
routine automatic segmentation, and coregistration algorithms is
the inability to account for significant tissue deformation, which
is particularly apparent in preclinical TBI models (Figure 2).
Thus, in general, the ROI-based method is preferred when there
is a hypothesis regarding a specific region, while the voxel-based
method is favored for whole brain data exploration.
PET ACQUISITION
As previously discussed, human PET scanners can acquire data
in 2D or 3D modes whereas preclinical scanners are generally
restricted to 3D mode only, without collimating septa. In 3D
mode, the septa are retracted or absent and data can be obtained
for all LORs. 3D mode increases the sensitivity significantly com-
pared to 2D mode but it suffers from reduced contrast due to
the abundance of scattered radiation. In order to integrate counts
over various time intervals, data can be acquired in list mode
with each event (coincidence detection) stored with a time stamp
identifying when the event occurred. This is usually less efficient
than storing data into sinograms, but allows the generation of
tissue-specific TACs that show activity uptake as a function of
time post injection. In order to avoid plotting the tracer expo-
nential decay function, voxel activity concentrations are typically
decay corrected to a specific time, usually the start of the scan or
the injection time. The TACs should only illustrate the changes
in physiological uptake and clearance, with all corrections for
acquisition, radiation decay, etc. already applied.
PET acquisitions are historically termed either static or
dynamic. A static acquisition occurs over a pre-defined time
period, with all events stored in a single sinogram to create a single
image. Static acquisition is typically initiated after tracer uptake
has peaked and/or after nonspecific tissue clearance, and the
count rate is determined for the entire acquisition time without
generating a TAC. In contrast, a dynamic PET acquisition usually
starts prior to tracer injection and is grouped into distinct frames
or time intervals. Dynamic studies provide an essential technique
for gating the image to support lung or heart imaging as well as
correcting motion artifacts observed during acquisition. It should
FIGURE 2 | T2-weighted MRI (TE = 60ms) of a male SD rat brain with
visible brain deformation 1 day post moderate CCI (left) and mild LFP
(right) injury. Focal tissue damage and associated hyperintense edema is
shown extending extracranially in both images.
be noted that absolute quantification and kinetic modeling of
uptake can only be accomplished with dynamically acquired data
and a blood input function as discussed in Human FDG Imaging.
General static and dynamic PET protocols for FDG imaging are
discussed in the following sections.
Human FDG imaging
18F-FDG is widely used clinically and in preclinical models of
various neurological disorders. The Society of Nuclear Medicine
(SNM) has written and approved procedural guidelines for FDG
brain imaging (Waxman et al., 2009). These guidelines should
be utilized consistently in order to compare imaging outcomes
across patients, platforms, and facilities. Once again, since plasma
glucose competes with FDG for uptake and elevated blood GLs
decrease the mean FDG uptake in the brain, blood glucose con-
centration levels should be evaluated prior to FDG administration
(Lindholm et al., 1993). The patient should fast for 4–6 h and
patient activity and social interactions should be minimized prior
to, during, and up to 30min post injection.
FDG activity. The activity administered is generally between 5
and 20mCi (185–740MBq) with an effective dose of 0.019mSv
per MBq. The accumulated effective dose should be carefully
considered when planning clinical studies, especially for studies
that include longitudinal PET imaging. For neuroimaging stud-
ies in children, administered FDG activity should be reduced to
0.14–0.20mCi/kg (5.18–7.4MBq/kg) for effective dose consider-
ations.
Static scan. A static scan implies that the detected counts are
summed over the entire duration of the acquisition to create a
single time-frame image. A typical static imaging protocol con-
sists of an emission scan (the actual PET scan) and a transmission
scan (a type of X-ray image) used for attenuation correction. The
FDG emission scan generally starts 30–60min post injection and
lasts up to 60min depending on several factors. For a modern
clinical 3D PET scanner, 10–20min of acquisition is usually ade-
quate for a brain scan. Transmission scans with a positron source
may be used if CT-based attenuation correction is not available.
The transmission scan device is built into the PET scanner and
has few user adjustable parameters.
Dynamic scan. Dynamic imaging protocols consist of a sequence
of images designed to capture the entire radiotracer uptake and
metabolism period. A dynamic FDG scan protocol typically
starts at FDG administration and ends at 90min post injection.
Dynamic studies are generally not used in routine clinical PET
imaging but can be found in research protocols. Accurate mea-
surements of the AIF, calibration factor, correction factors, and
FDG and baseline glucose plasma levels are required in order
to determine the kinetic rate and regional metabolic rates of
FDG. The AIF requires direct serial blood sampling to determine
changes in the arterial FDG concentration over time. Ideally, the
blood is sampled from an artery, commonly the iliac artery, which
is somewhat invasive and unpleasant for the patient. Alternatively,
blood can be acquired from a vein, but the preceding capillaries
must be “arterialized” using a heat bath to cause the capillaries to
dilate to minimize extraction of FDG by the capillary bed. This
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is likewise inconvenient for both patient and clinician. For non-
invasive measurements of the AIF, it is possible to generate an
image-derived input function by analyzing large vascular regions
on the PET image (de Geus-Oei et al., 2006).
Uptake factors. Factors that maymodify FDG uptake or become a
source of error include the use of medications that may alter cere-
bral metabolism, hyperglycemia, patient motion during the scan
or between emission and transmission scans, and interpretation
of relative quantitation data.
Small animal FDG imaging
PET brain imaging of FDG and the evaluation of regional glucose
metabolism in small animals is technically challenging and con-
strained by the limited spatial resolution of most PET scanners
(approximately 1.5mm). Typically, similar or better resolution is
obtained for humans in terms of the ratio of the spatial resolution
compared to the volume of interest; animal scanners have better
spatial resolution compared to a clinical human scanner, but most
animal brain structures are proportionately smaller. Also, factors
such as administration route, dietary condition, uptake environ-
ment, and anesthesia type can affect the uptake of FDG in mice
and rats. It is imperative that these factors be controlled for or
standardized in most in vivo FDG studies. Each prominent factor
will be briefly discussed.
Administration route. Typically, FDG is administered through
a bolus intravenous tail-vein injection (IV). This administration
route is efficient and eliminates the need for solute absorption but
is also challenging and necessitates proper animal handling and
skilled technicians who maintain proficiency. Partial extravascu-
lar or paravenous tail vein injections are a common complica-
tion that can confound study outcomes. Error rates in tail vein
injections are not readily available and are most likely underre-
ported. Intraperitoneal (IP) injection is a convenient and practical
administration route for smaller species for which intravenous
access is difficult. FDG uptake is slower after IP injection due to
additional absorption via the portal system, but the FDG biodis-
tributions in mice after 60min of uptake is not significantly
different between IP and IV injections (Fueger et al., 2006; Wong
et al., 2011). In rats, one study showed that 19.6% of IP injec-
tions conducted by trained staff members had placement errors
(Turner et al., 2011). Similar studies of IP injection errors in mice
indicate 12–24% placement error despite extra careful one-man
handling and injection procedures and a 1.2% error rate with a
two-man procedure (Miner et al., 1969; Arioli and Rossi, 1970).
The convenience of IP injection should be weighed against the
slower distribution times, which may reduce facility through-
put, and the risk of injecting FDG into an organ instead of the
peritoneal cavity. Lastly, the volume of administration should be
carefully monitored since low activity concentrations can lead to
large injection volumes that may require slow infusion rates.
Dietary conditions. Since both FDG and glucose use the same
process to enter cells, changes in plasma glucose can affect FDG
through competitive uptake. Similar to humans, fasted mice and
rats prior to FDG injection show a significant increase in brain
uptake of FDG—a two-fold increase for mice not anesthetized
during uptake (Fueger et al., 2006). In contrast, glucose load-
ing to establish hyperglycemia has been shown to significantly
reduce brain uptake of FDG (Ishizu et al., 1994). For kinetic mod-
eling, the uptake constant (Ki) varies inversely with blood GL.
Assuming a fixed LC, the metabolic rate of glucose (MRGlu) con-
sumption is independent of blood GL or flow (Wong et al., 2011).
When animals are fasted in order to artificially increase brain
uptake of FDG, the fasting time should be strictly controlled since
plasma GLs depend on fasting time (Nowland et al., 2011).
Uptake environment. The biodistribution of FDG depends on
the activity and temperature of the animal during the uptake
period. Animals that are conscious during uptake show variable
distributions in the brain depending on the overall activity level
(i.e., resting or active). Animals under anesthesia show depressed
FDG uptake and less heterogeneity, which might be preferable
when measuring small changes. In our own work, we have found
that maintenance of anesthesia during the FDG uptake period is
essential to limit inter and intra-subject variability. Since main-
taining equal resting/activity levels amongst animals during the
uptake period is essential for longitudinal comparisons of FDG
uptake in the brain, we have found that anesthesia is the best
method to ensure equal activity despite the lower signal. In a small
pilot study of mild LFP TBI, we compared FDG uptake after a
30-min uptake period and 30-min scan, in which three rodents
were anesthetized and three were not, and we found that anes-
thesia significantly reduced inter-animal variability (Figure 3).
Warming mice, whether conscious or unconscious, during the
uptake period increases brain uptake of FDG. Overall, the great-
est FDG uptake is observed with conscious, fasted and warmed
animals. It is important to note that uptake in conscious ani-
mals shows a 3-fold variation depending on the environmental
conditions, whereas unconscious animals show less than a 2-fold
variation.
Anesthesia. As previously discussed, animals under anesthesia
show reduced brain uptake of FDG. In addition, anesthesia causes
hypothermia and warming is essential. However, it is standard
practice and usually advantageous to anaesthetize animals for the
FIGURE 3 | FDG uptake, normalized to sham, at baseline (time 0), 3
and 24h after a mild LFP showed less variability and greater
depression when animals were anesthetized during uptake than when
animals were awake during uptake. N = 3/group.
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duration of the experiment unless the experimental goals dictate
otherwise. Several studies have compared the effect of different
types of anesthesia on glucose metabolism (Lenz et al., 1998;
Matsumura et al., 2003; Toyama et al., 2004b; Fueger et al., 2006;
Martic-Kehl et al., 2012). Sevoflurane and isoflurane similarly
reduce the mean cerebral glucose utilization both globally and
locally in many brain regions. Compared to ketamine alone, it
has been found that ketamine + xylazine, chloral hydrate, pen-
tobarbital, propofol, and isoflurane all induce lower brain uptake
of FDG (Matsumura et al., 2003). When compared to conscious,
free moving rats, ketamine anesthetized rats showed only a very
slight decrease in FDG uptake but a different regional distribu-
tion. In addition, when any anesthesia was initiated 40min after
FDG injection, there was no statistical difference from uptake in a
conscious rat. The glucose utilization in frontal, parietal, tempo-
ral, and occipital cortex was significantly reduced in mice under
isoflurane compared to conscious mice. Caution should also be
taken when conducting surgeries or other imaging procedures
involving anesthesia directly prior to FDG injection. Anesthesia
has been shown to increase plasma GLs (isoflurane or ketamine+
xylazine) or plasma insulin (pentobarbital) (Lee et al., 2005;
Wong et al., 2011). As stated earlier, elevated levels of plasma
glucose will competitively reduce brain FDG uptake, although
glucose metabolic rates will remain relatively constant. This is an
important effect to consider when calculating uptake values or
metabolic rates.
FDG-PET AND TBI
With a good understanding of the FDG-PET technique and lim-
itations, it is now possible to provide a review of the current
literature detailing the outcomes of FDG-PET after mTBI. In
reviewing the literature, it became apparent that several studies
have been conducted using various FDG-PET techniques to mea-
sure glucose uptake and metabolism after TBI, and some of these
techniques are not consistent between laboratories. Many of the
clinical studies provide sparse information regarding the quan-
tification method utilized to analyze FDG-PET images, which can
affect replication efforts. Despite these limitations and concerns,
patterns of FDG uptake and, in some cases, metabolism can be
observed after mTBI and are discussed below.
CLINICAL mTBI STUDIES
FDG-PET has been used clinically to study TBI in various
patient populations with 10 published reports evaluating FDG-
PET after mTBI, excluding cases of complicated mTBI where
damage was observed on the CT or MRI scan after an appar-
ent mild injury. These published results demonstrate varying
degrees of sensitivity to detection at acute, subacute, and chronic
phases of injury. Acute, subacute, and chronic phases are loosely
defined and are determined by the clinician based on patient
stability and clinical interventions. Most recently, the phases of
injury were defined by Diaz-Arrastia et al. as <1 day (acute), 1
day–1 week (subacute), 1 week–6 months (post-acute), and >6
months (chronic)(Diaz-Arrastia et al., 2013). Of the currently
available clinical studies of mTBI in Table 1, most have inves-
tigated the chronic phase (8 of 10) and many have claimed
to evaluate the global or regional MRGlc, although only three
studies provided estimates of rate constants or kinetic modeling
information.
The earliest in vivo FDG-PET study of MRGlc after mTBI
was a 1989 examination by Humayun et al. (1989), in which
the global and local MRGlc in three patients who had expe-
rienced chronic symptoms after a motor vehicle accident were
compared with three normal control patients using FDG-PET
during a vigilance task. The MRGlc was estimated using rate
constants and LCs previously reported by Huang et al. and nor-
malized to the global metabolic rate (Huang et al., 1980). While
this study saw no global changes in glucose metabolism, regional
reductions in metabolism were observed in the posterior tem-
poral and posterior frontal cortices and the caudate nucleus at
3–12 months after injury. In addition, this study was the first to
show increased metabolism in the anterior temporal and ante-
rior frontal cortices at post-acute to chronic time points. In 1994,
Ruff et al. qualitatively evaluated nine chronic mTBI cases that
demonstrated unexpected neuropsychological deficits and were
considered outliers given the extent of the injury (Ruff et al.,
1994). Patients received the Continuous Performance Test (CPT)
during the 30–35min dynamic PET scan and the cortex and sub-
cortical regional metabolic rates were normalized to whole brain
or whole slice metabolic rate (Nuechterlein et al., 1983). The
quantification technique is not provided but readers are referred
to Buchsbaum et al., 1982 and 1989 publications (Buchsbaum
et al., 1982, 1989). Hypoactivity in the frontal and temporal
cortex at approximately 29 months was correlated with neu-
ropsychological testing and was observed in frontal and anterior
temporal regions but the sample size was too small to compare
size and extent of hypoactive regions. Gross et al. also investigated
FDG-PET in 20 chronic mTBI cases with 17 patients demon-
strating only brief, if any, LOC (Gross et al., 1996). Local MRGlc
was determined while the patient participated in the CPT, as
reported by Ruff et al. (1994). Similar to Ruff, PET quantifica-
tion details were not reported and the reader was referred to
work by Sokoloff et al. (1977). The Gross study is expected to
be consistent with Ruff et al. since Dr. Buchsbaum was involved
in both PET studies. Abnormal activity in the temporal region
was correlated with attention/concentration and memory prob-
lems at approximately 43 months post TBI. Several regions of
the brain showed increased or decreased glucose metabolism with
the most frequent abnormalities observed in the midtemporal,
anterior cingulate, precuneus, frontal white, anterior temporal,
and mid and postcingulate, with a tendency toward increased
metabolism in the temporal and frontal white regions. Overall,
there are large variations in glucose metabolism outcomes from
task-based FDG-PET studies, yet studies have consistently mea-
sured hypometabolism in the frontal and temporal regions after
mTBI despite being statistically underpowered.
Four other studies have investigated mTBI in the general pop-
ulation with FDG-PET but did not quantify metabolic rates.
Roberts et al. and Abu-Judeh et al. both report a case study of
a single mTBI case (Roberts et al., 1995; Abu-Judeh et al., 1998).
Roberts et al. show a reduction in FDG uptake in both tempo-
ral lobes and cerebellar hemispheres 4 years after whiplash injury
in an 11-years old boy (Roberts et al., 1995). Abu-Judeh et al.
report normal FDG uptake in a 28-years old female at 2 days
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post injury (Abu-Judeh et al., 1998). FDG uptake was normal-
ized to the cerebellum and remained normal despite a reduction
in cortical brain perfusion. Both studies lack significance but
provide novel information in pediatric TBI and in the early sub-
acute setting. In 2002, Umile et al. utilized descriptive statistics
based on a clinical interpretation of resting PET to estimate
“normal” to “abnormal” uptake in 13 patients in the post-acute
and chronic phases (Umile et al., 2002). Abnormalities based
on Single Photon Emission Computed Tomography (SPECT)
and FDG-PET were observed in temporal and frontal lobes of
mTBI cases but the PET results were not specifically discussed.
Approximately 85% of patients had positive findings on molecu-
lar imaging studies and neuropsychological testing but metabolic
deficits did not always correspond with dysfunction. In contrast,
Chen et al. reported no significant difference in the regional
FDG uptake during resting state PET in frontal and temporal
regions of five mildly injured patients with chronic symptoms
(Chen et al., 2003). However, ROIs were normalized to the cal-
carine cortex, which was not evaluated as a valid reference region,
which might have confounded results. To date, decreased rest-
ing state FDG uptake in the temporal and frontal lobes has been
reported in 19 cases of mTBI with chronic symptoms. This result
is relatively consistent between uptake studies and metabolic
studies despite the obvious differences in quantification and
methodologies.
TBI is sometimes referred to as the signature injury of
Operation Enduring Freedom and Operation Iraqi Freedom, and
blast injury has become a common source of mTBI (Hoge et al.,
2008, 2009). Three recent studies have evaluated chronic mTBI in
veterans using FDG-PET. Peskind et al. were the first to observe
hypometabolism in the cerebellum and medial temporal lobe
of war veterans due to repetitive blast exposure (Peskind et al.,
2011). A 20-min PET scan was performed on 12 veterans and
NEUROSTAT software (University of Washington, Seattle, WA)
was used to normalize FDG uptake to global brain activity and
to estimate metabolic rates. Specific details of the PET acquisition
were not provided. Despite the large variability in injury (3–51
blasts) and evaluation times post injury (2–5 years), decreased
MRGlc was estimated in the infratentorial structures (cerebel-
lum, vermis, and pons) andmedial temporal cortex in correlation
with persistent post-concussive symptoms. In 2013, Mendez et al.
compared blunt force and blast induced mTBI using FDG-PET in
24 war veterans (Mendez et al., 2013). Static 15-min PET scans
were conducted after 45min of resting FDG uptake and ana-
lyzed using NeuroQ™ software (Syntermed Inc. Atlanta, GA).
Standardized ROIs (41) were normalized to the mean whole brain
activity and compared to normative PET data derived from 50
normal subjects. Of the 41 ROIs, 15 showed abnormal uptake
for blast and blunt force groups. Hypometabolism was generally
observed in the right superior parietal cortex, left inferior frontal,
inferolateral anterior temporal, left posterior cingulate, and left
thalamus. Compared to the blunt force cohort, the blast group
unexpectedly showed reduced uptake in the right superior pari-
etal region not the frontotemporal region. However, significant
correlations between poor cognitive measurements and decreased
FDG uptake were only observed in the left medial frontal area
of the blast group, which could indicate parietal-frontal network
dysfunction. The most recent study by Petrie et al. compared nor-
malized FDG uptake in 34 veterans who experienced between 1
and 100 blasts to 18 veterans without blast injury (Petrie et al.,
2013). Specific details of the PET acquisition were not provided.
To avoid using an unstable reference region for normalization,
intensities were normalized to the mean whole brain uptake.
Reduced normalized FDG uptake was observed in parietal cor-
tices, left somatosensory cortex, and right visual cortex. Uptake
values within the parahippocampal gyrus were lower for veter-
ans exposed to more versus fewer than 20 blast mTBIs. Currently,
we are evaluating our own clinical FDG-PET images obtained
from veterans with various injuries at various stages post-TBI
(Figure 4).
A majority of the studies that have evaluated FDG uptake
(via SUV or RUV) or MRGlc have shown reductions in regional
metabolism after mTBI. This finding is remarkable given the large
variation in methodologies and parameters measured. For exam-
ple, PET imaging was conducted from 2 days to 7 years post
injury; the type of injury ranged from falls to repetitive blast expo-
sures; severity of TBI included stunned, brief LOC, and several
hour LOC; ages ranged between 11–69 years with both male and
female subjects represented; PET imaging was conducted in both
resting and active states; and quantitation included kinetic mod-
eling for MRGlc, estimated parameters for MRGlc, and various
reference regions for uptake normalization. Overall, MRGlc and
FDG uptake measures show a similar trend of reduced global and
regional activity. Depending on the kinetic model and the level
of parameter estimation (LC, rate constants, blood volume), this
result indicates a reduction in both uptake and also glucose uti-
lization. Yet, the 2004 study by Wu et al. revealed a potentially
controversial finding, a significant reduction in the global and
regional [gray matter (GM)] LC due to reduced hexokinase activ-
ity (k3) in severe TBI patients (Wu et al., 2004a). A reduction in
hexokinase activity may suggest impaired mitochondrial function
or protein dysregulation after TBI.
If this reduction in LC for severe TBI is also present in
mTBI, then studies that determine the MRGlc with the standard
population-based LC may show a reduced metabolic rate (see
Equation 1), while studies that determine the MRFDG will also
observe a decrease that is independent of LC. Thus, both mea-
surements are expected to show the same trend despite differences
in methodologies. This phenomenon is also observed in preclin-
ical rat oncologic studies where the LC is considerably larger for
gliomas compared to normal cortex due to an increase in phos-
phorylation in gliomas (Kapoor et al., 1989). It should be noted
that there is no direct method to determine the regional LC.
Additionally, the large variation in the design of clinical stud-
ies makes comparing outcomes difficult. Initial studies reviewed
above show a clear pattern of sustained hypometabolism or
depressed uptake in a variety of specific brain regions—regions
that may be particularly sensitive to TBI. Overall, studies have
observed alterations in glucose metabolism and/or uptake after
mTBI in both global measures and in specific regions such as the
midtemporal, anterior cingulate, precuneus, anterior temporal,
frontal white, and corpus callosum brain regions (Ruff et al., 1994;
Gross et al., 1996; Umile et al., 2002), right superior parietal cor-
tex (Mendez et al., 2013) and infratentorial (cerebellum, vermis,
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FIGURE 4 | Standard FDG-PET images from three clinical TBI cases. (A)
25 y.o. male, single non-blast moderate TBI, imaged 5 months post-injury. No
recorded medications or sleep difficulties, pain/headache, or vision problems.
FDG-PET shows left temporal hypometabolism associated with mild volume
loss/encephalomalacia on the CT. (B) 28 y.o. male, single non-blast severe
TBI, imaged 12.5 months post-injury. No recorded medications or sleep
difficulties, pain/headache, or vision problems. FDG-PET shows a more
severe injury with prominent hypometabolism frontally (arrow) associated
with encephalomalacia. (C) 35 y.o. male, history of repeat exposure to
blast-related mTBI, imaged 43 months post-injury. Pain medication (ultram),
mild body pain, and moderate sleep problems, no findings CT. FDG-PET
shows prominent frontal hypermetabolism, which may be medication
related. The color bar displayed in (C) applies to all images with red
representing greater FDG uptake.
pons) areas (Peskind et al., 2011). Future studies using FDG-PET
in TBI should consider: (1) carefully defining the patient selection
criteria in order to account for variables such as injury type, injury
history, age, time between injury, and PET scan; (2) utilizing a
standard PET acquisition protocol and image analysis method;
and (3) selecting controls to match patients based on age, gender,
and education.
PRECLINICAL mTBI STUDIES
The utilization and investigation of FDG-PET in mTBI preclin-
ical studies is even more sparse than in clinical research, which
is not surprising considering the limited availability of dedicated
small animal PET scanners, the limited number of facilities that
can administer an experimental mTBI, and the challenge in mea-
suring subtle changes in FDG uptake after mTBI. To the best of
our knowledge, only one publication has reported outcomes from
FDG-PET measurements after mTBI in animal models (Table 2).
In 2013, we investigated the longitudinal FDG-PET response
after an mTBI induced using a LFP in Sprague Dawley (SD) rats
(Selwyn et al., 2013). In this study, the mild LFP TBI with an esti-
mated impact pressure of 1.25 atm resulted in transient motor
deficits, no lesion formation or neuronal loss, and marked axonal
damage. Animals were anesthetized with isoflurane for the tail
vein injection of FDG and during the 45-min uptake period.
After uptake, a 30-min 3D static PET scan was acquired. FDG
uptake in the central brain was normalized to the cerebellum and
showed a transient depression, with a peak depression of approx-
imately 15% below baseline at 24 h post-injury, followed by a
slow return to baseline levels by 9–15 days post-injury. This acute
reduction at 24 h was significantly correlated with an increase in
astrocyte immunolabeling at 9 days post-injury. Reduced uptake
was observed in the sub-lesion white and GM (encompassing the
corpus callosum, hippocampus and other deep GM structures) as
well as in a smaller ROI encompassing the cortex directly beneath
the craniotomy. Histology of these same structures indicated that
these regions also showed evidence of elevated microglial activity,
reduced axonal profiles and reduced myelination.
This study showed a pattern of reduced uptake that is similar
to those patterns observed in clinical mTBI, although the differ-
ent acquisition and quantitation techniques raise some concerns
about the comparability of the results. For future studies, just as
with clinical studies, it is essential to limit physiological varia-
tions and to standardize imaging procedures. The experimental
mTBI model is a significant factor and characterizing the FDG
uptake or glucose metabolism in multiple models of mTBI would
aid in the translational aspect of the results. Further, standardiza-
tion of the acquisition and quantitation techniques should allow
for comparisons across injury models and labs. In our work, we
have identified two factors that are essential to limit inter-animal
variability: (1) maintenance of anesthesia during the FDG uptake
period, and (2) reference region normalization. However, fur-
ther work is needed to explore specific cellular and functional
correlates with FDG measurements.
CLINICAL AND PRECLINICAL STUDIES IN MODERATE AND SEVERE TBI
Over the last 20 years, FDG-PET imaging after moderate to severe
TBI has garnered more attention than mTBI. In moderate to
severe TBI research, a general trend in FDG uptake and glucose
metabolism has been established in both animal (Figure 5) and
clinical studies. This trend shows an acute increase in glucose
utilization in some regions, followed by a sustained depression
or hypometabolism in the subacute or chronic phase—a bipha-
sic response in some regions. A majority of the FDG studies
combine data from acute, subacute and chronic phases and also
severe, moderate, and complicated mTBI. This aggregation may
confound results.
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FIGURE 5 | Representative diagram of FDG uptake as measured by PET
imaging, normalized to reference region, based on animal modeling.
The representative lines are drawn from data from our work on mTBI
(Selwyn et al., 2013) and the work of others on moderate to severe TBI (Liu
et al., 2010; Shultz et al., 2013).
Significant contributions to the overall knowledge of FDG-
PET in TBI have been made by the UCLA group comprised
of Drs. Wu, Hattori, Huang, Vespa, Bergsneider, and Hovda.
Together, they account for over 30% of the publications reporting
FDG-PET results in TBI (Table 3). The UCLA group has imple-
mented a consistent technique to measure MRGlc and has mainly
focused on severe, moderate, and complicated mild in the acute
to subacute phase. Despite a decrease in cerebral metabolism after
severe TBI, in 1997 Bergsneider et al. were the first to report suba-
cute global and regional hyperglycolysis up to 2 weeks after severe
TBI based on measurements of cerebral metabolic rate of oxy-
gen (CMRO2) and MRGlc (Bergsneider et al., 1997). In 2000,
Bergsneider et al. reported depressed global MRGlc in 84% of TBI
patients between 2 and 28 days after injury with a few patients
demonstrating elevated MRGlc in the first week (Bergsneider
et al., 2000). Overall, an elevated MRGlc was observed in only
a small fraction of TBI patients within the first 5 days and was
followed by a sustained depression in glucose metabolism lasting
weeks to months (Bergsneider et al., 2001). While Bergsneider
did not show a correlation between global cortical MRGlc and
level of consciousness, Hattori et al. showed that regional MRGlc
values for the thalamus, brain stem, and cerebellum significantly
correlated with the level of consciousness at 5 days after severe
TBI (Hattori et al., 2003). Wu et al. further investigated regional
changes by comparing GM to white matter (WM) in the acute
to subacute phase (Wu et al., 2004b). Confirming diffuse WM
injury after moderate and severe TBI, Wu et al. showed a reduc-
tion in the CMRO2 without an associated decrease in MRGlc in
WM and demonstrated that a focal injury can extend beyond the
suspected abnormality. It should be noted that Wu was the first
to calculate the MRGlc using a TBI-specific global LC, which was
based on previous work that showed a significant reduction in
the LC following TBI (Wu et al., 2003, 2004a). Vespa et al. con-
ducted a robust study comparing the lactate to pyruvate ratio
(LPR) from microdialysis to PET measurements of CMRO2 and
MRGlc in the acute and subacute phase of severe TBI (Vespa
et al., 2005). LPR was negatively correlated with CMRO2 but was
not correlated with MRGlc and was not specific for brain injury.
Ultimately, multitracer PET studies have not observed ischemia
in GM or WM remote from the lesion site and show a com-
bination of regional and global hyperglycolysis. These analyses
have excluded the pericontusional areas. Hence, the most recent
study byWu et al. focused on the contusional and pericontusional
region and the normal appearing GM surrounding the injury site
(Wu et al., 2013).MRGlc appeared altered depending on the prox-
imity to the injury and the cellular composition (Wu et al., 2013).
In the acute to subacute phase of injury, the MRGlc is great-
est in pericontusional regions that have dense cellular make-up
but is reduced in regions with fewer cells or in regions closer
to the lesion epicenter. This pattern generally matched CMRO2
but the relationship between oxidative and glucose metabolism
suggested a non-ischemic shift to anaerobic metabolism. Overall,
the UCLA research team has provided consistent FDG-PET
research that has shed new light on and answered fundamen-
tal questions regarding the metabolism crisis after moderate to
severe TBI.
Several other laboratories have conducted additional studies
to investigate specific regions with altered glucose metabolism or
FDG uptake after moderate to severe TBI (Table 4). However,
unlike the studies conducted at UCLA, outcomes from these
studies are difficult to compare due to differences in acquisition
protocols, quantification techniques, patient selection, and stage
of injury. Several researchers have investigated resting uptake of
FDG while a few have conducted task-based uptake studies after
moderate to severe TBI, which is similar to work by Humayun,
Ruff, and Gross in mTBI. For example, in 1999, Lombardi et al.
measured decreased MRGlc in the dorsal prefrontal cortex, puta-
men, frontal poles, and caudate during an attention task in
patients diagnosed with severe, chronic TBI (Lombardi et al.,
1999). Zhang et al. conducted the largest task-based FDG-PET
study published to date and included severe, moderate, and mTBI
patients (81) at post injury times between 0 and 11 years (Zhang
et al., 2010). FDG uptake during a Serial Verbal Learning Task
was normalized to the whole brain uptake using SPM and showed
lower relative uptake across the cortex, bilateral and temporal
regions, and thalamus. Yet, in contrast to other studies, Zhang
showed increased uptake in the cingulate gyrus, hippocampus,
and amygdala, whichmay reflect a compensatory response or dys-
function in attention or memory during task. Again, results from
task-based FDG-PET studies are widely variable and should be
carefully interpreted.
In 1997, Alavi et al. observed decreased FDG uptake in the ipsi-
lateral and contralateral cerebellum of patients with focal cortical
or extraparenchymal injury, termed crossed cerebellar diaschi-
sis, in the subacute to chronic phases (Alavi et al., 1997). This
phenomenon is not observed with diffuse brain injuries. Thus,
the cerebellum should be carefully validated as a stable refer-
ence tissue before using this region to normalize focal injuries
in human FDG-PET studies. In regards to diffuse TBI, Fontaine
et al. published results from a severe TBI cohort in the post-acute
to chronic phase without evidence of focal contusion (Fontaine
et al., 1999). The resting state FDG-PET showed a significant
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reduction in the global MRGlc and in the regional MRGlc of
the prefrontal and cingulate cortex. Disorders in memory, exec-
utive function, and behavior were correlated with the cingulate
gyrus metabolism. Nakayama et al. conducted a study of dif-
fuse TBI without focal injury and measured reduced normalized
FDGuptake, using SPM software, in themedial prefrontal, medial
frontobasal, cingulate gyrus, and thalamus (Friston et al., 1994;
Nakayama et al., 2006). From the same research group, Kato et al.
investigated diffuse TBI in a similar cohort but with focal injury
and showed reduced normalized uptake using SPM in the bilat-
eral frontal lobes, temporal lobes, thalamus, and right cerebellum
(Kato et al., 2007). It should also be noted that a positive correla-
tion between IQ and regional glucose metabolism was observed
in the cingulate gyrus and medial frontal gyrus, which could
confound metabolic studies, especially in diffuse TBI.
In a novel TBI cohort comprised of 22 boxers, Provenzano
et al. reported decreased SUVs in the frontal lobe, posterior cin-
gulate gyrus, posterior parietal lobe, and cerebellum (Provenzano
et al., 2010). These results are similar to other modes of brain
injury with differences possibly due to the repetitive hits to the
side of the head. Overall, for moderate to severe TBI in the
post-acute to chronic stage, the thalamus, and the frontal and
temporal regions show a consistent reduction in resting state
FDG uptake or MRGlc, while FDG uptake in the cingulate gyrus
may be influenced by attention tasks or baseline intelligence,
which could confound results (Lull et al., 2010a,b; Garcia-Panach
et al., 2011). Also, with significant focal injuries, the cerebellum
consistently shows reduced glucose metabolism that may reflect
network dysfunction.
In animal models of moderate to severe brain injury, similar
sustained hypometabolism and reduced uptake has been noted.
In these studies, the majority of evaluations were performed using
normalization of glucose uptake to a reference region (Table 2),
with a few studies employing SUV analysis. However, only a sin-
gle study utilized MRGlc measurements, most likely due to the
difficulty in performing repeated blood draws in animals (Moore
et al., 2000). In this report, the MRGlc was determined at baseline
and at day 2, 5, and 10 after moderate LFP injury. The PET scan
was initiated after 42min of resting, conscious uptake. The great-
est decrease in the MRGlc was observed at approximately 2 days
post-injury and in the ipsilateral frontal cortex, parietal cortex,
caudate-putamen, and thalamus with recovery by 10 days.
In moderately injured animals assessed using reference region
normalization, the uptake alterations resolved within 10–14 days
(Zhang et al., 2008). However, with more severe injuries, sus-
tained alterations in glucose uptake have been observed. For
example, reduced uptake in FDG-PET scans of rat hippocampus
at 1 week, 1 month, 3 months, and 6 months after a severe LFP
injury (3.2–3.5 atm) has been reported (Liu et al., 2010; Shultz
et al., 2013). Furthermore, severe TBI studies have shown slow
recovery in FDG uptake, with incomplete recovery by 3 months
(Chen et al., 2004). Using SUV measurements, Guan et al. found
significant reductions in FDG uptake in the lesion area at 5 weeks
after a moderate to severe CCI injury (Guan et al., 2013).
In 2012, Li et al. investigated FDG-PET after a novel accel-
eration model of diffuse axonal injury in adult male SD rats
(Li et al., 2012). This injury model was previously described
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and was designed to mimic severe diffuse injury in humans (Li
et al., 2010). Animals were fasted for 24 h prior to PET imag-
ing to ensure stable glucose metabolism and anesthetized for
PET imaging. The 3D static PET protocol was initiated immedi-
ately upon FDG intravascular injection and was conducted over
45min. SUVs were calculated for each voxel in the sensorimotor
cortex, hippocampus, corpus callosum, caudate putamen, brain
stem, and cerebellum at days 1, 3, 7, and 30 after injury, utiliz-
ing MRI-based ROIs. Global and regional SUVs were reduced at
days 1, 3, and 7 after injury in comparison to sham-injured uptake
values. These changes were significantly correlated with cognitive
impairment as measured by Morris Water Maze at 90 days post-
injury; however, significant reduction in swim speed may indicate
that observed differences could be due to motor rather than
cognitive deficiencies. This novel diffuse injury induces severe
hypometabolism acutely that was significantly correlated with
dysfunction in learning and memory.
CORRELATION WITH FUNCTION AND HISTOLOGY
Beyond its ability to detect alterations in the brain after injury,
a correlation between FDG-PET measurements and motor or
cognitive function (preclinical and clinical) or tissue histology
(preclinical) is essential in demonstrating the utility of the imag-
ing modality. In our 2013 publication, we demonstrated that,
in an animal model of mTBI, FDG uptake was transiently sup-
pressed with a peak depression at 24 h (Selwyn et al., 2013). This
peak depression was significantly correlated with immunolabel-
ing for astrocyte reactivity at 9 days post-injury, suggesting that
acute glucose uptake alterations can possibly predict future glial
activation.
Structurally, reduced glucose uptake has been correlated with
regional atrophy after moderate to severe TBI in several clini-
cal studies. For example Xu et al. found that reduced glucose
metabolism in the frontal lobes was significantly correlated with
cellular atrophy in that same region (Xu et al., 2010). In animal
models, the dissociation between glucose uptake and blood flow
acutely after a moderate TBI has been correlated with regions
of axonal damage (Harris et al., 2012). In a well-designed study,
this group demonstrated that improving blood flow at the time
of elevated glucose demand using acetazolamide reduced axonal
damage.
In clinical studies, hypometabolism as measured by FDG-PET
after mTBI has been correlated with attention deficits (Humayun
et al., 1989; Gross et al., 1996; Mendez et al., 2013), increased
irritability, social withdrawal, sleep and memory problems, and
depression (Gross et al., 1996). In more severe TBI, Hattori
et al. showed that FDG-PET measures in the thalamus, brain-
stem and cerebellum were significantly correlated with level of
consciousness at the time of PET imaging (Hattori et al., 2003).
Severe TBI in preclinical studies has shown a correlation
between depressed glucose uptake and seizure occurrence (Shultz
et al., 2013). However, in terms of function, little correlation has
been established to date between FDG-PET measures and func-
tional assessments. For example, Liu et al. found that there was
no correlation between FDG-PET at 1 week or 1, 3, or 6 months
after injury and performance on an open field test, an elevated
plus maze, and learning and memory in a Morris Water Maze test
after a severe injury (Liu et al., 2010). However, a more severe
injury, involving implantation of a probe into a rodent brain, did
demonstrate co-occurrence of memory problems with reduced
FDG uptake (Frumberg et al., 2007). This study, however, failed
to perform a correlation analysis to show that the co-occurrence
was significant.
After an mTBI in animal models, results have differed from
those observed with a more severe injury. Depression in FDG
uptake, particularly in the hippocampus, has been correlated
with poor performance in the Morris Water Maze at 1 month
after injury, although it should be noted that the same animals
also demonstrated impairments in motor ability that were not
discussed by the authors (Li et al., 2012).
FDG-PET IN OTHER MODELS OF CNS INJURY
Clinical studies and animal models have had success with FDG-
PET for both diagnosis and prognosis of other CNS injuries
besides TBI, correlating glucose uptake with injury size, severity
and recovery. Clinical studies of cervical myelopathy demon-
strate that FDG-PET is sensitive enough to track focal increases
in FDG uptake in sites of spinal cord stenosis correlated with
improved clinical outcomes, and FDG-PET SUV of impaired
metabolic activity have been correlated with deterioration of
function (Uchida et al., 2004; Floeth et al., 2011). Further, com-
parison of FDG-PET andMRI have shown that SUV in FDG-PET
correlate better with postoperative neurological outcomes than
MRI (Uchida et al., 2012), indicating that FDG-PET offers more
sensitive parameters for determining postoperative outcomes.
FDG-PET has been used as a non-invasive longitudinal imaging
tool for animal models as well. In a rat model of contusion spinal
cord injury (SCI), reductions in FDG uptake activity at the injury
site were measured when compared to uninjured cord (Nandoe
Tewarie et al., 2010). Rat models of ischemia have used FDG-PET
to detect metabolic variations as markers of predicting tissue fate
or recoverability (Fu et al., 2009; Walberer et al., 2012) and have
shown FDG-PET to be more sensitive to metabolic alterations
in the ischemic core at earlier time points post-injury (Sobrado
et al., 2011). FDG-PET has also been useful for tracking novel
treatment outcomes of ischemia, as demonstrated by recent work
with transplantation of bone marrow stromal cells for improve-
ment in cerebral glucose metabolism (Miyamoto et al., 2013).
These studies demonstrate a potential for this modality to be
used in determination of spread of an injury with time as well
as for discriminating viable tissue from injured for therapeutic
targeting.
The findings from these studies demonstrate that FDG-PET is
specific enough for diagnosis of regionally specific injuries and
can be more sensitive than MRI or traditional neurological test-
ing, making it a viable modality for a variety of CNS injury
models, in both human and rodent models. However, FDG-PET
in regions of the CNS outside the brain likely requires individ-
ual characterization to account for size differences and metabolic
activity of adjacent organs, as seen in spinal cord. Overall, work
in these regions to date demonstrates a viable modality for track-
ing both severity and recovery to injury over time. However,
differences in methodologies may limit the correlation between
various, potentially comparable studies.
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CONCLUSION
In conclusion, FDG-PET allows for the evaluation of glucose
uptake and utilization in the brain after injury. However, care
must be taken in both study design and image analysis, since sev-
eral factors can impact the final results. In particular, future work
should: (1) consider the role of the LC in evaluating the MRGlc,
(2) further standardize the TBI imaging protocol to include sub-
ject status during FDG uptake and PET scan, (3) stratify data
based on the stage of injury at the time of the PET scan (i.e.,
acute, subacute, chronic) and type of injury or mechanism, and
(4) identify a robust image processing and analysis technique
(e.g., SPM) and a FDG parameter to serve as a reproducible
biomarker of injury (SUV, RUV, MRGlc, MRFDG, etc.). These
recommendations apply to preclinical and clinical studies of TBI.
Despite these concerns, the literature and our own work have
demonstrated a broad pattern of sustained brain hypometabolism
or depressed brain uptake of FDG in relatively consistent regions
of the brain that may last for days to months after a mild brain
injury. While still preliminary, this reduction is similar to the pat-
tern observed after a more severe brain injury and is correlated
with both cellular and functional alterations post-TBI. These out-
comes demonstrate the potential importance of FDG and the
need for future research on FDG to assess and monitor brain
function after mTBI.
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